Listed by the USPTO as ROBINSON, HOPE A
Tech Center 1600 • Art Units: 1637 1652 1656
This examiner grants 68% of resolved cases
ROBINSON, HOPE A is assigned to tech center 1600 and art unit 1637. The profile records 1058 resolved cases and an allowance rate of 67.7%. Median time to allowance is 1213 days, making timing an important factor in portfolio and client planning.
Interview lift is 43.0%, identifying interviews as a substantial feature of the recorded outcomes. The listed companies are University of Florida Research Foundation Inc., Morgan State University, and Université Paris-Saclay. The listed firms are SALIWANCHIK, LLOYD & EISENSCHENK, WILSON SONSINI GOODRICH & ROSATI, and NIXON & VANDERHYE, PC. Practitioners may benefit from preparing detailed interview positions that connect proposed amendments to the technical record.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18598468 | IL-1RA CDNAS | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18236078 | PROTEIN-PEG INTERACTIONS THAT REDIRECT THE THERMAL UNFOLDING PATHWAY OF PEGYLATED HUMAN GALECTIN-3C | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED |
| 18555956 | ENZYMATICALLY-CLEAVABLE GLYCIDYL METHACRYLATE HYALURONIC ACID | Non-Final OA | University of Florida Research Foundation, Inc. |
| 18851734 | PROCESS FOR PRODUCING CELLULOLYTIC AND/OR HEMICELLULOLYTIC ENZYMES | Non-Final OA | IFP ENERGIES NOUVELLES |
| 18262318 | METHOD FOR SIZE BASED EVALUATION OF PANCREATIC PROTEIN MIXTURE | Final Rejection | Kashiv BioSciences, LLC |
| 18632426 | USE OF BIOMARKERS TO DETERMINE WHETHER A SUBJECT HAS SUSTAINED, MAY HAVE SUSTAINED OR IS SUSPECTED OF SUSTAINING A SUBACUTE ACQUIRED BRAIN INJURY (ABI) | Non-Final OA | Abbott Laboratories |
| 19334536 | COMPOSITIONS AND METHODS FOR CONTROLLING PLANT PESTS | Final Rejection | Confluence Genetics, LLC |
| 18340046 | MICROORGANISMS FOR DITERPENE PRODUCTION | Final Rejection | DSM IP ASSETS B.V. |
| 18031691 | RELATIVE UNPAIRED GLYCANS IN ANTIBODY PRODUCTION METHODS | Final Rejection | AMGEN INC. |
| 18005086 | POLYNUCLEOTIDE ENCODING AN AMINO ACID SEQUENCE, ENCODING AN OXIDOREDUCTASE | Final Rejection | Evonik Operations GmbH |
| 18787311 | METHODS FOR ENGINEERING OUTER MEMBRANE VESICLE PRODUCTION AND CARGO PACKAGING IN PSEUDOMONAS PUTIDA | Non-Final OA | Alliance for Energy Innovation, LLC |
| 18326099 | METHOD AND DEVICE FOR DETECTING TRANSGLUTAMINASES | Final Rejection | TECHNISCHE UNIVERSITÄT DARMSTADT |
| 18863705 | GENETICALLY MODIFIED YEAST AND FERMENTATION PROCESSES FOR THE PRODUCTION OF ARABITOL | Non-Final OA | Cargill, Incorporated |
| 18871339 | MEANS AND METHODS FOR REDUCING PHOSPHORUS SECRETION BY FISH | Non-Final OA | NOVOZYMES A/S |
| 18857409 | PROCESS FOR PRODUCING FREE FATTY ACIDS | Non-Final OA | Novozymes A/S |
| 17843589 | NON-NATURAL MICROBIAL ORGANISMS WITH IMPROVED ENERGETIC EFFICIENCY | Final Rejection | Genomatica, Inc. |
| 18867974 | NUCLEIC ACID MODIFIED TO OBTAIN ENHANCED ERGOTHIONEINE PRODUCTIVITY, AND MICROORGANISM HAVING GENETIC MODIFICATION | Non-Final OA | KIKKOMAN CORPORATION |
| 17916441 | ADAMTS13 VARIANT, COMPOSITIONS, AND USES THEREOF | Non-Final OA | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18812083 | C1-ESTERASE INHIBITOR PREPARATION | Non-Final OA | OCTAPHARMA AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy67.7% of resolved applications examined by Hope A Robinson were allowed (1,058 resolved cases), compared with 45.4% across Art Unit 1637 over the last five years.
This examiner's interview lift is +43.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Hope A Robinson took 1,213 days on average from filing to allowance.
Hope A Robinson examines applications in Art Unit 1637 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
